Tritherapy Article (ALA/HCA/ Chemotherapy), Tables
Supplementary tables
Suppl. Table 1a. Statistical analysis of mean tumor growth curves in LLC model (Figure 1a).
Analysis using linear mixed models showed that the linear time trends of tumor volume for the six groups differed significantly(F5,182.7 = 22.7, P < 0.001).Results are expressed as β (see material & methods for definition) with 95% CI as compared to cisplatin (CIS).
Group / β value / CI 95% / P valueALA/HCA / -1.13 / -6.08 to 1.64 / 0.3
ALA/OCT / 3.08 / 2.14 to 9.78 / 0.002
HCA/OCT / 3.39 / 2.75 to 10.39 / 0.001
OCT / -0.58 / -5.13 to 2.80 / 0.6
ALA/HCA/OCT / -4.51 / -10.33 to -4.04 / 0.001
Suppl. Table 1b. Statistical analysis of median survival in LLC model (Figure 1b).
The log-rank test (Mantel-Cox) was used to compare differences in the distributions of tumor failure times of each treatment group with their respective control group. Results are expressed as median with 95% CI as compared to cisplatin (CIS).
Group / median survival (days) / CI 95% / P valueVEHICLE / 43.2 / 41.7 to 44.6 / -
CIS / 52.1 / 47.9 to 56.4 / -
ALA/HCA / 56.7 / 50.2 to 63.2 / 0.001
ALA/OCT / 50.5 / 46.5 to 54.4 / 0.417
HCA/OCT / 51.0 / 49.2 to 52.8 / 0.603
OCT / 51.7 / 46.6 to 56.9 / 0.125
ALA/HCA/OCT / 77.6 / 71.2 to 84.1 / 0.001
Suppl. Table 2a. Statistical analysis of mean tumor growth curves in MBT2 model (Figure 2a).
Analysis using linear mixed models showed that the linear time trends of tumor volume for the four groups differed significantly (F3,127.3 = 52.4, P < 0.001). Results are expressed as β (see material & methods for definition) with 95% CI as compared to cisplatin (CIS).
Group / β value / CI 95% / P valueALA/HCA / -0.39 / -3.12 to 2.09 / 0.7
OCT / -0.39 / -3.12 to 2.09 / 0.7
ALA/HCA/OCT / -9.12 / -11.80 to -7.59 / P < 0.001
Suppl. Table 2b. Statistical analysis of median survival in MBT2 model (Figure 2b).
The log-rank test (Mantel-Cox) was used to compare differences in the distributions of tumor failure times of each treatment group with their respective control group.
Group / median survival (days) /CI 95%
/ P value vs VEHICLE / P value vs CISVEHICLE / 44.6 / 41.7 to 47.4 / -
CIS / 52.5 / 50.5 to 54.4 / 0.001 / -
ALA/HCA / 53.6 / 51.3 to 55.9 / P < 0.001 / 0.950
OCT / 48.6 / 46.9 to 50.3 / 0.001 / 0.02
ALA/HCA/OCT / 76.4 / 68.1 to 84.6 / 0.002 / 0.001
Suppl. Table 3a. Statistical analysis of mean tumor growth curves in B16F10 model as compared to cisplatin (Figure 3a).
Analysis using linear mixed models showed that the linear time trends of tumor volume for the four treated groups differed significantly (F3,115.6 = 95.0, P < 0.001). Results are expressed as β (see material % methods for definition) with 95% CI as compared to CIS.
Group / β value / CI 95% / P valueALA/HCA / -0.35 / -2.99 to 2.20 / 0.8
OCT / 1.72 / -0.38 to 5.40 / 0.09
ALA/HCA/OCT / -10.80 / -14.63 to -10.09 / P < 0.001
Suppl. Table 3b. Statistical analysis of median survival in B16-F10 model as compared to cisplatin (Figure 3b).
The log-rank test (Mantel-Cox) was used to compare differences in the distributions of tumor failure times of each treatment group with their respective control group.
Group / median survival (days) / CI 95% / P value vs VEHICLE / P value vs CISVEHICLE / 39.3 / 37.4 to 41.2
CIS / 45.9 / 45.1 to 46.6 / 0.001
ALA/HCA / 47.3 / 46.1 to 48.5 / < 0.001 / 0.247
OCT / 42.8 / 39.6 to 46.0 / 0.027 / 0.002
ALA/HCA/OCT / 70.9 / 67.8 to 74.0 / 0.001 / 0.001
Suppl. Table 4. Statistical analysis of mean tumor growth curves in NCI-H69 model as compared to CIS (Figure 4).
Analysis using linear mixed models showed that the linear time trends of tumor volume for the treated groups differed significantly (F4,53.8 = 5.87, P = 0.001). Results are expressed as β (see material & methods for definition) with 95% CI as compared to CIS.
Group / β value / CI 95% / P valueALA/HCA/OCT / 0.003 / -0.001 to 0.008 / 0.18
1/4